GLP-1 Myths vs Facts: Separating Hype from Science for Indians

GLP-1 Myths vs Facts: Separating Hype from Science for Indians

Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) and liraglutide (Saxenda, Victoza) have generated more myths, misconceptions, and outright misinformation in India than almost any medication in recent memory. WhatsApp forwards, Instagram reels, and overconfident online forums have created a fog of confusion.

This guide examines nine of the most common myths circulating in Indian communities — and what the actual clinical evidence says.

Consult your healthcare provider before starting any medication.

---

Why Myths Spread So Fast in India

Several factors make GLP-1 misinformation particularly persistent in India:

• High stakes: These are expensive medications (₹8,000–₹25,000/month) — people want certainty
• WhatsApp culture: Medical claims spread without fact-checking
• Limited physician awareness: Many Indian doctors are not yet fully updated on newer GLP-1 trial data
• No trusted Hindi resource: Most evidence-based content is in English

---

Myth 1: "GLP-1 is just a shortcut — you'll regain all the weight when you stop"

Verdict: Partially true, but deeply misleading

Yes, weight typically does return after stopping GLP-1 — studies show 60–70% of lost weight is regained within 1–2 years of stopping (STEP 1 trial extension, NEJM 2022). However, calling this a "shortcut" misunderstands the nature of obesity.

The full picture:

• Obesity is a chronic disease with strong biological drivers — insulin resistance, hypothalamic dysregulation, and leptin resistance make weight maintenance biologically difficult
• GLP-1 medications treat these biological drivers, just as blood pressure medication treats hypertension
• The STEP 5 trial showed sustained weight loss of 15.2% over 2 years with continuous semaglutide use
• During the medication period, people establish new eating habits and gain significant metabolic health improvements

What this means for Indians: Work with your doctor on a long-term maintenance strategy. GLP-1 is most effective as part of a comprehensive plan — not a standalone quick fix.

---

Myth 2: "These medications cause cancer"

Verdict: False for most people — one specific contraindication applies

This myth stems from a real but specific concern: thyroid C-cell tumours were observed in rodent studies with semaglutide. However:

• These tumours appeared at doses far exceeding human doses
• The mechanism appears rodent-specific — C-cell density in humans differs
• No causal link between GLP-1 medications and human thyroid cancer has been established
• Multiple large-scale trials with hundreds of thousands of patient-years have not shown increased cancer rates

The actual contraindication: GLP-1 medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

For everyone else, current evidence does not support cancer concern as a reason to avoid these medications. Pancreatitis (not cancer) remains a known rare risk — discussed with your doctor.

---

Myth 3: "You can get semaglutide from overseas for ₹2,000"

Verdict: Dangerous and likely counterfeit

India has seen a surge in counterfeit and substandard GLP-1 products:

• "Semaglutide powder" sold online for compounding
• Suspiciously cheap injections from grey-market pharmacies
• Products claiming to be "generic Ozempic" from unverified sources

Why this is dangerous:

• Semaglutide requires cold-chain storage (2–8°C) — compromised products lose efficacy
• Counterfeit pens have been globally reported (WHO advisory, June 2023)
• Unregulated dosing risks severe hypoglycemia in diabetics

Legitimate cost benchmarks in India (2024–2025):

• Ozempic 0.5mg/0.25mg (Novo Nordisk): ₹7,000–₹9,000/pen (4 doses)
• Rybelsus (oral semaglutide): ₹4,500–₹7,000/month
• Saxenda (liraglutide): ₹8,000–₹12,000/pen

If the price seems too good to be true, it is.

---

Myth 4: "GLP-1 medications are only for diabetics"

Verdict: False — major indications now include obesity

The landscape has evolved significantly since the first GLP-1 approvals:

• Ozempic (semaglutide 0.5–2mg): CDSCO-approved for type 2 diabetes
• Wegovy (semaglutide 2.4mg): Approved for chronic weight management (BMI ≥30, or ≥27 with weight-related condition)
• Saxenda (liraglutide 3mg): Available in India for weight management
• Rybelsus (oral semaglutide): Approved for type 2 diabetes

Indian doctors increasingly prescribe these medications for weight management in patients without diabetes — a recognised, evidence-based practice.

---

Myth 5: "You don't need to change your diet on GLP-1"

Verdict: False — diet remains essential

GLP-1 medications reduce appetite and slow gastric emptying, but they do not:

• Neutralise the metabolic impact of ultra-processed foods
• Prevent weight plateau (which occurs in most patients by month 6–9)
• Compensate for inadequate protein intake — which leads to muscle loss
• Directly address insulin resistance without dietary change

Indian diet context: The average Indian diet is high in refined carbohydrates (white rice, maida, fried snacks) and low in protein. On a GLP-1 medication, this is particularly problematic — reduced appetite makes it easy to under-eat protein, leading to muscle loss alongside fat loss.

Minimum targets on GLP-1:

• Protein: 60–80g daily (100g+ preferred)
• Vegetables: 2–3 cups daily
• Ultra-processed foods: minimise

---

Myth 6: "Ozempic face / aging changes are permanent"

Verdict: Partially true but manageable — and not specific to semaglutide

"Ozempic face" refers to facial volume loss from rapid weight loss — it is not a specific drug effect. When you lose 10–20% body weight:

• Facial fat pads decrease
• Skin may appear more lax

What the evidence shows:

• This is primarily a weight-loss phenomenon — any method of significant weight loss causes it
• Slow, steady weight loss (0.5–1kg/week) reduces severity
• Adequate protein and strength training help preserve facial muscle
• For most people, facial appearance stabilises within 6–12 months

Indian context: Darker skin types common in Indians have more natural collagen density, which may reduce the severity of this effect compared to what is widely reported in Western populations.

---

Myth 7: "These are new, untested medications"

Verdict: False — GLP-1 medications have 15–20 years of evidence

• Exenatide (first GLP-1 agonist): FDA approved 2005 — 20 years of real-world data
• Liraglutide (Victoza): FDA approved 2010
• Semaglutide (Ozempic): FDA approved 2017
• Semaglutide for obesity (Wegovy): FDA approved 2021

The SELECT trial (2023) enrolled 17,604 participants and showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease — even in those without diabetes. This is among the largest cardiovascular outcomes trials in history.

---

Myth 8: "Vegetarians and Jains can't use GLP-1 injections"

Verdict: Nuanced — discuss with your doctor and religious authority

This concern arises frequently in Indian communities:

• Semaglutide itself is a synthetic peptide — not derived from animal sources
• Some excipients in formulations may have animal-derived origins — check the specific product insert
• Rybelsus (oral tablets) does not list animal-derived excipients
• Many religious scholars have ruled that medical necessity permits medication use even if trace animal-derived components are present

Consult both your physician and your religious authority for guidance specific to your situation and belief system.

---

Myth 9: "Higher doses work faster — I should start at the maximum"

Verdict: False and potentially harmful

GLP-1 medications follow a strict titration protocol for good reason:

• Starting at high doses causes severe nausea, vomiting, and diarrhoea in the majority of patients
• The gradual increase allows GI tract adaptation
• Most serious GI adverse events in clinical practice occur from dose-jumping
• Starting high does not produce meaningfully faster weight loss — the benefit curve is not linear

Standard semaglutide titration (weekly injection):

• Weeks 1–4: 0.25mg/week
• Weeks 5–8: 0.5mg/week
• Weeks 9–12: 1mg/week (adequate for many patients)
• Beyond: titrate only as needed and tolerated, under doctor supervision

---

Quick Reference: Myth Verdict Table

| Claim | Verdict | |-------|---------| | Weight returns when you stop | Largely true — long-term plan needed | | Causes cancer | False — specific contraindications apply | | Available cheap online | Dangerous — likely counterfeit | | Only for diabetics | False — approved for obesity too | | No need to change diet | False — diet is essential | | Ozempic face is permanent | False — manageable and temporary | | Too new to trust | False — 15–20 years of evidence | | Vegetarians can't use it | Nuanced — discuss with your doctor | | Higher dose = faster results | False — follow prescribed titration |

---

When to Talk to Your Doctor About What You've Heard

1. Write down the claim exactly as you heard it
2. Bring it to your next consultation
3. Ask for the clinical evidence behind the claim
4. Check PubMed, CDSCO, or WHO before believing WhatsApp forwards

The most dangerous myth of all is that you can make informed decisions about prescription medications without professional guidance.

Consult your healthcare provider before starting any medication. This article is for informational purposes only and does not constitute medical advice.